Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Adult Malignant Glioma Therapeutics Market: By Therapy: Radiotherapy, Chemotherapy, Targeted therapy, Others; By Disease: Anaplastic Astrocytoma, Others; By End Use; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments

Global Adult Malignant Glioma Therapeutics Market Outlook

The global market for adult malignant glioma therapeutics reached a value of USD 1.84 billion in 2021. The market is further expected to grow at a CAGR of about 9.2% in the forecast period of 2022-2027 to reach a value of around USD 3.13 billion by 2027, owing to the growing cases of brain tumour.

 

North America and Asia Pacific to be the Significant Regional Markets for Adult Malignant Glioma Therapeutics

North America is anticipated to dominate the global market due to the presence of major product manufacturers, high research and development (R&D), growing healthcare expenditure, and trained personnel. Technological innovation is a major market driver in North America. According to the National Library of Medicine, approximately 17,000 new high-grade gliomas (HGG) cases are diagnosed in the United States each year. Primary malignant brain tumours account for approximately 3% of all cancer deaths, the majority (around 80%) of which are HGG . The rise in the incidence of the disease, a strong economy, high diagnosis rate owing to the awareness about healthcare among the population are the other major factors driving the adult malignant glioma therapeutics market.

Due to an increase in government awareness programmes and the number of generic drugs, Asia Pacific is estimated to account for the largest market share for adult malignant glioma therapeutics in the forecast period. The market's growth, however, is likely to be determined by the combined prospects in technology and opportunity in developing Asian countries such as China, Japan, India, and South Korea. The relatively large patient population requiring affordable care and improvements in health care infrastructure in rapidly developing countries that aid in the early detection of malignant gliomas are likely to drive the adult malignant glioma therapeutics market.

 

Market Segmentations

Malignant brain tumours have a profound effect on both those who receive and those who deliver the diagnosis. Malignant gliomas, the most prevalent subtype of primary brain tumours, are aggressive, highly invasive, and neurologically damaging tumours that are among the most fatal human diseases.

The different therapies provided by the market are:

  • Radiotherapy
  • Chemotherapy
  • Targeted therapy
  • Others

Based on disease, the market is divided into:

  • Anaplastic Astrocytoma
  • Glioblastoma Multiforme
  • Anaplastic Oligodendroglioma
  • Others

The end-uses of the market are:

  • Speciality Clinics
  • Hospitals
  • Cancer and Radiation Therapy Centres
  • Others

The regional markets for adult malignant glioma therapeutics can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

 

Rising Prevalence of Cancer Related Disorders Propelling the Market Growth

The rising prevalence of cancer-related disorders worldwide and growing cases of brain tumours are the major factors driving the adult malignant glioma therapeutics market. The adoption of an unhealthy lifestyle, genetic modification/alteration, increased age, excessive exposure to radiation and family history with brain cancer are also propelling the market growth. Further, increased advancements in cancer treatment, a fast-expanding pipeline of innovative novel medications, and increased government support to accelerate the process of orphan drug approval are expected to bolster the market growth during the projection period. However, high treatment costs, loss of market exclusivity, post-patent expiration, and price reductions in branded drugs owing to competition from generic brands may impede the market growth.

Technological advancements in diagnosing glioma and analysing its progression through various imaging modalities are accelerating the market growth. For example, researchers have developed a new imaging technique that may help eliminate the malignant tumour from the human body. This imaging method may help surgeons locate the tumour with ease. The method also involves using an infra-red (IR) camera and an imaging reagent tozuleristide (BLZ-100). The agent contains a synthetic version of an amino acid compound found in scorpion venom. The primary goal of this procedure was to distinguish between healthy and tumour tissue. This aids in the retention of healthy tissue following surgery, increasing the overall efficiency of the procedure . Such discoveries are likely to favour the growth of the global adult malignant glioma therapeutics market in the coming years.

 

Key Players in the Global Market for Adult Malignant Glioma Therapeutics

The report gives a detailed analysis of the following key players in the global adult malignant glioma therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Arbor Pharmaceuticals, LLC
  • AbbVie Inc.
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2021
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Therapy
  • Disease
  • End Use
  • Region
Breakup by Therapy
  • Radiotherapy
  • Chemotherapy
  • Targeted therapy
  • Others
Breakup by Disease
  • Anaplastic Astrocytoma
  • Glioblastoma Multiforme
  • Anaplastic Oligodendroglioma
  • Others
Breakup by End Use
  • Speciality Clinics
  • Hospitals
  • Cancer and Radiation Therapy Centres
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Arbor Pharmaceuticals, LLC
  • AbbVie Inc.
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Adult Malignant Glioma Therapeutics Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Adult Malignant Glioma Therapeutics Historical Market (2017-2021) 
    8.3    Global Adult Malignant Glioma Therapeutics Market Forecast (2022-2027)
    8.4    Global Adult Malignant Glioma Therapeutics Market by Therapy
        8.4.1    Radiotherapy
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Chemotherapy
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Targeted therapy
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2021)
            8.4.3.3    Forecast Trend (2022-2027)
        8.4.4    Others
    8.5    Global Adult Malignant Glioma Therapeutics Market by Disease
        8.5.1    Anaplastic Astrocytoma
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Glioblastoma Multiforme
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Anaplastic Oligodendroglioma
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2021)
            8.5.3.3    Forecast Trend (2022-2027)
        8.5.4    Others
    8.6    Global Adult Malignant Glioma Therapeutics Market by End Use
        8.6.1    Speciality Clinics
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2017-2021)
            8.6.1.3    Forecast Trend (2022-2027)
        8.6.2    Hospitals
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2017-2021)
            8.6.2.3    Forecast Trend (2022-2027)
        8.6.3    Cancer and Radiation Therapy Centres
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2017-2021)
            8.6.3.3    Forecast Trend (2022-2027)
        8.6.4    Others    
    8.7    Global Adult Malignant Glioma Therapeutics Market by Region
        8.7.1    North America
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2017-2021) 
            8.7.1.3    Forecast Trend (2022-2027)
        8.7.2    Europe
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2017-2021) 
            8.7.2.3    Forecast Trend (2022-2027)
        8.7.3    Asia Pacific
            8.7.3.1    Market Share
            8.7.3.2    Historical Trend (2017-2021) 
            8.7.3.3    Forecast Trend (2022-2027)
        8.7.4    Latin America
            8.7.4.1    Market Share
            8.7.4.2    Historical Trend (2017-2021) 
            8.7.4.3    Forecast Trend (2022-2027)
        8.7.5    Middle East and Africa
            8.7.5.1    Market Share
            8.7.5.2    Historical Trend (2017-2021) 
            8.7.5.3    Forecast Trend (2022-2027)
9    North America Adult Malignant Glioma Therapeutics Market Analysis
    9.1    United States of America 
        9.1.1    Market Share
        9.1.2    Historical Trend (2017-2021) 
        9.1.3    Forecast Trend (2022-2027)
    9.2    Canada
        9.2.1    Market Share
        9.2.2    Historical Trend (2017-2021) 
        9.2.3    Forecast Trend (2022-2027)
10    Europe Adult Malignant Glioma Therapeutics Market Analysis
    10.1    United Kingdom
        10.1.1    Market Share
        10.1.2    Historical Trend (2017-2021) 
        10.1.3    Forecast Trend (2022-2027)
    10.2    Germany
        10.2.1    Market Share
        10.2.2    Historical Trend (2017-2021) 
        10.2.3    Forecast Trend (2022-2027)
    10.3    France
        10.3.1    Market Share
        10.3.2    Historical Trend (2017-2021) 
        10.3.3    Forecast Trend (2022-2027)
    10.4    Italy
        10.4.1    Market Share
        10.4.2    Historical Trend (2017-2021) 
        10.4.3    Forecast Trend (2022-2027)
    10.5    Others
11    Asia Pacific Adult Malignant Glioma Therapeutics Market Analysis
    11.1    China
        11.1.1    Market Share
        11.1.2    Historical Trend (2017-2021) 
        11.1.3    Forecast Trend (2022-2027)
    11.2    Japan
        11.2.1    Market Share
        11.2.2    Historical Trend (2017-2021) 
        11.2.3    Forecast Trend (2022-2027)
    11.3    India
        11.3.1    Market Share
        11.3.2    Historical Trend (2017-2021) 
        11.3.3    Forecast Trend (2022-2027)
    11.4    ASEAN
        11.4.1    Market Share
        11.4.2    Historical Trend (2017-2021) 
        11.4.3    Forecast Trend (2022-2027)
    11.5    Australia
        11.5.1    Market Share
        11.5.2    Historical Trend (2017-2021) 
        11.5.3    Forecast Trend (2022-2027)
    11.6    Others
12    Latin America Adult Malignant Glioma Therapeutics Market Analysis
    12.1    Brazil
        12.1.1    Market Share
        12.1.2    Historical Trend (2017-2021) 
        12.1.3    Forecast Trend (2022-2027)
    12.2    Argentina
        12.2.1    Market Share
        12.2.2    Historical Trend (2017-2021) 
        12.2.3    Forecast Trend (2022-2027)
    12.3    Mexico
        12.3.1    Market Share
        12.3.2    Historical Trend (2017-2021) 
        12.3.3    Forecast Trend (2022-2027)
    12.4    Others
13    Middle East and Africa Adult Malignant Glioma Therapeutics Market Analysis
    13.1    Saudi Arabia
        13.1.1    Market Share
        13.1.2    Historical Trend (2017-2021) 
        13.1.3    Forecast Trend (2022-2027)
    13.2    United Arab Emirates
        13.2.1    Market Share
        13.2.2    Historical Trend (2017-2021) 
        13.2.3    Forecast Trend (2022-2027)
    13.3    Nigeria
        13.3.1    Market Share
        13.3.2    Historical Trend (2017-2021) 
        13.3.3    Forecast Trend (2022-2027)
    13.4    South Africa
        13.4.1    Market Share
        13.4.2    Historical Trend (2017-2021) 
        13.4.3    Forecast Trend (2022-2027)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Value Chain Analysis
16    Competitive Landscape

    16.1    Market Structure
    16.2    Company Profiles
        16.2.1    Merck & Co., Inc.
            16.2.1.1    Company Overview
            16.2.1.2    Product Portfolio
            16.2.1.3    Demographic Reach and Achievements
            16.2.1.4    Certifications
        16.2.2    F. Hoffmann-La Roche Ltd
            16.2.2.1    Company Overview
            16.2.2.2    Product Portfolio
            16.2.2.3    Demographic Reach and Achievements
            16.2.2.4    Certifications
        16.2.3    Arbor Pharmaceuticals, LLC
            16.2.3.1    Company Overview
            16.2.3.2    Product Portfolio
            16.2.3.3    Demographic Reach and Achievements
            16.2.3.4    Certifications
        16.2.4    AbbVie Inc.
            16.2.4.1    Company Overview
            16.2.4.2    Product Portfolio
            16.2.4.3    Demographic Reach and Achievements
            16.2.4.4    Certifications
        16.2.5    Others
17    Key Trends and Developments in the Market

 

List of Key Figures and Tables

1.    Global Adult Malignant Glioma Therapeutics Market: Key Industry Highlights, 2017 and 2021
2.    Global Adult Malignant Glioma Therapeutics Historical Market: Breakup by Therapy (USD Billion), 2017-2021
3.    Global Adult Malignant Glioma Therapeutics Market Forecast: Breakup by Therapy (USD Billion), 2022-2027
4.    Global Adult Malignant Glioma Therapeutics Historical Market: Breakup by Disease (USD Billion), 2017-2021
5.    Global Adult Malignant Glioma Therapeutics Market Forecast: Breakup by Disease (USD Billion), 2022-2027
6.    Global Adult Malignant Glioma Therapeutics Historical Market: Breakup by End Use (USD Billion), 2017-2021
7.    Global Adult Malignant Glioma Therapeutics Market Forecast: Breakup by End Use (USD Billion), 2022-2027
8.    Global Adult Malignant Glioma Therapeutics Historical Market: Breakup by Region (USD Billion), 2017-2021
9.    Global Adult Malignant Glioma Therapeutics Market Forecast: Breakup by Region (USD Billion), 2022-2027
10.    North America Adult Malignant Glioma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
11.    North America Adult Malignant Glioma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
12.    Europe Adult Malignant Glioma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
13.    Europe Adult Malignant Glioma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
14.    Asia Pacific Adult Malignant Glioma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
15.    Asia Pacific Adult Malignant Glioma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
16.    Latin America Adult Malignant Glioma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
17.    Latin America Adult Malignant Glioma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
18.    Middle East and Africa Adult Malignant Glioma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
19.    Middle East and Africa Adult Malignant Glioma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
20.    Global Adult Malignant Glioma Therapeutics Market Structure

Key Questions Answered in the Report

In 2021, the global adult malignant glioma therapeutics market attained a value of nearly USD 1.84 billion.

The market is projected to grow at a CAGR of 9.2% between 2022 and 2027.

The market is estimated to witness a healthy growth in the forecast period of 2022-2027 to reach USD 3.13 billion by 2027.

The major drivers of the market include the growing cases of brain tumours, adoption of an unhealthy lifestyle, excessive exposure to radiation, family history with brain cancer, fast-expanding pipeline of innovative novel medications, increased government support, and technological advancements.

The rising prevalence of cancer-related disorders and increased advancements in cancer treatment are the key industry trends propelling the growth of the market.

The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The different therapies provided by the market are radiotherapy, chemotherapy, and targeted therapy, among others.

Based on disease, the market is divided into anaplastic astrocytoma, glioblastoma multiforme, and anaplastic oligodendroglioma, among others.

The end-uses of the market are speciality clinics, hospitals, and cancer and radiation therapy centres, among others.

The major players in the industry are Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, LLC, and AbbVie Inc., among others.

Analyst Review

The global adult malignant glioma therapeutics market attained a value of nearly USD 1.84 billion in 2021, driven by the rising prevalence of cancer-related disorders. Aided by the growing cases of brain tumours and fast-expanding pipeline of innovative novel medications, the market is expected to grow at a CAGR of 9.2% in the forecast period of 2022-2027. The market is estimated to reach USD 3.13 billion by 2027.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The different therapies provided in the market include radiotherapy, chemotherapy, and targeted therapy, among others. Based on disease, the market is divided into anaplastic astrocytoma, glioblastoma multiforme, and anaplastic oligodendroglioma, among others. The treatment finds end-uses in speciality clinics, hospitals, cancer and radiation therapy centres, among others. The major regional markets for adult malignant glioma therapeutics are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The key players in the above market are Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, LLC, and AbbVie Inc., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 2199     $1799
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 3199     $2999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$ 4199     $3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 5199     $4999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER